Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer.

Masmudur M Rahman Fleur van Oosterom Junior A Enow Maksuda Hossain Ami D Gutierrez-Jensen Mackenzie Cashen Anne Everts Kenneth Lowe Jacquelyn Kilbourne Juliane Daggett-Vondras Timothy L Karr Grant McFadden

Published in: Cancer research communications (2023)

We demonstrated that a combination of nuclear export inhibitor selinexor and oncolytic MYXV significantly enhanced viral replication, reduced cancer cell proliferation, reduced tumor burden, and enhanced the overall survival of animals. Thus, selinexor and oncolytic MYXV can be used as potential new anticancer therapy.

Keyphrases

papillary thyroid
cell proliferation
squamous cell
sars cov
lymph node metastasis
stem cells
bone marrow
mesenchymal stem cells
young adults
replacement therapy